Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
Article Category: Research Article
Data publikacji: 30 lis 2023
Zakres stron: 436 - 445
Otrzymano: 05 cze 2023
Przyjęty: 25 wrz 2023
DOI: https://doi.org/10.2478/raon-2023-0055
Słowa kluczowe
© 2023 Maria Ingenerf et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Background
This study aimed to evaluate the predictive and monitoring role of somatostatin receptor (SSTR) positron emission tomography-computed tomography (PET/CT) and clinical parameters in patients with neuroendocrine liver metastases (NELM) from pancreatic neuroendocrine tumors (pNET) receiving capecitabine and temozolomide (CAPTEM).
Patients and methods
This retrospective study included twenty-two patients with pNET and NELM receiving CAPTEM who underwent pre- and post-therapeutic 68Ga-DOTATATE/-TOC PET/CT. Imaging (including standardized uptake value [SUV] of target lesions [NELM and pNET], normal spleen and liver) and clinical (Chromogranin A [CgA], Ki-67) parameters were assessed. Treatment outcome was evaluated as response according to RECIST 1.1, progression free survival (PFS) and overall survival (OS).
Results
The median PFS (mPFS) was 7 months. Responders had a significantly longer mPFS compared to non-responders (10
Conclusions
SSTR-PET/CT can be useful for predicting response and survival outcomes in pNET patients receiving CAPTEM: Higher baseline SUV values, particularly Tmax/Smean ratios of liver metastases were associated with better response and prolonged PFS.